Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
aberrant, administered, advertising, age, agonist, American, antagonist, ARPA, assigned, beneficial, bythe, cohort, consumption, conventional, counterparty, deuterated, difficulty, disintegrating, dosage, dry, duringthe, ease, Evionnaz, experienced, generallyinclude, inability, infrequent, instantly, inthree, LAI, mild, molecular, monitor, monitored, mood, mouth, ona, PDUFA, Rescue, SA, saleable, Siegfried, Similarly, solid, stable, strategy, subcutaneously, sublingual, swallowing, tablet, therapeutic, thousand, tongue, Top, tothe, transient, uncollectible, uniquely, vendor, volume
Removed:
accommodate, acquiring, AD, aggression, agitation, Alzheimer, autism, breakout, cognitive, Committee, creation, depended, developed, discontinuation, dysfunction, emergent, existed, expanding, fiscal, free, fully, hiring, Huntington, implement, implemented, investigate, investigation, merit, moderate, noting, partner, pipeline, sNDA, spectrum, strain, underway, varied, vested
Filing tables
Filing exhibits
Associated ITCI transcripts
ITCI similar filings
Filing view
External links
Exhibit 32
CERTIFICATIONS UNDER SECTION 906
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Intra-Cellular Therapies, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:
The Quarterly Report for the quarter ended March 31, 2021 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: May 10, 2021 | /s/ Sharon Mates, Ph.D. | |||||
Sharon Mates, Ph.D. | ||||||
Chairman, President and Chief Executive Officer | ||||||
(principal executive officer) | ||||||
Dated: May 10, 2021 | /s/ Lawrence J. Hineline | |||||
Lawrence J. Hineline | ||||||
Senior Vice President of Finance and Chief Financial Officer | ||||||
(principal financial officer) 1 |